3692 Stock Overview
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 3692 from our risk checks.
Hansoh Pharmaceutical Group Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$19.56 |
| 52 Week High | HK$21.00 |
| 52 Week Low | HK$9.73 |
| Beta | 0.61 |
| 11 Month Change | 8.79% |
| 3 Month Change | 18.69% |
| 1 Year Change | 81.45% |
| 33 Year Change | 0.10% |
| 5 Year Change | -15.69% |
| Change since IPO | -21.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3692 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -2.4% | 3.4% | 6.8% |
| 1Y | 81.4% | 11.8% | 8.2% |
Return vs Industry: 3692 exceeded the Hong Kong Pharmaceuticals industry which returned 11.8% over the past year.
Return vs Market: 3692 exceeded the Hong Kong Market which returned 8.2% over the past year.
Price Volatility
| 3692 volatility | |
|---|---|
| 3692 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 4.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in HK Market | 13.5% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 3692 has not had significant price volatility in the past 3 months.
Volatility Over Time: 3692's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 9,099 | Huijuan Zhong | www.hspharm.com |
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.
Hansoh Pharmaceutical Group Company Limited Fundamentals Summary
| 3692 fundamental statistics | |
|---|---|
| Market cap | HK$115.85b |
| Earnings (TTM) | HK$5.23b |
| Revenue (TTM) | HK$13.43b |
21.8x
P/E Ratio8.5x
P/S RatioIs 3692 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3692 income statement (TTM) | |
|---|---|
| Revenue | CN¥12.10b |
| Cost of Revenue | CN¥1.09b |
| Gross Profit | CN¥11.01b |
| Other Expenses | CN¥6.30b |
| Earnings | CN¥4.71b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.80 |
| Gross Margin | 91.01% |
| Net Profit Margin | 38.97% |
| Debt/Equity Ratio | 0.1% |
How did 3692 perform over the long term?
See historical performance and comparison